Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

SEHK:2196 Stock Report

Market Cap: HK$65.2b

Shanghai Fosun Pharmaceutical (Group) Past Earnings Performance

Past criteria checks 0/6

Shanghai Fosun Pharmaceutical (Group)'s earnings have been declining at an average annual rate of -5.9%, while the Pharmaceuticals industry saw earnings growing at 4.3% annually. Revenues have been growing at an average rate of 9.6% per year. Shanghai Fosun Pharmaceutical (Group)'s return on equity is 4.7%, and it has net margins of 5.1%.

Key information

-5.9%

Earnings growth rate

-6.8%

EPS growth rate

Pharmaceuticals Industry Growth5.6%
Revenue growth rate9.6%
Return on equity4.7%
Net Margin5.1%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Shanghai Fosun Pharmaceutical (Group) makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

SEHK:2196 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2441,6112,11413,5123,839
30 Jun 2440,4671,83513,3934,074
31 Mar 2440,6862,00913,9384,207
31 Dec 2341,4002,38614,1984,346
30 Sep 2343,0293,57814,3794,595
30 Jun 2343,9993,97214,3584,609
31 Mar 2344,4374,26113,7144,461
31 Dec 2243,9523,73113,0614,302
30 Sep 2243,5863,60012,7304,286
30 Jun 2243,4063,78212,5854,103
31 Mar 2241,3404,33812,5144,006
31 Dec 2139,0114,72912,4013,837
30 Sep 2135,2534,74911,6953,332
30 Jun 2133,2314,43011,6363,153
31 Mar 2132,4833,93311,6822,944
31 Dec 2030,3073,66311,2042,795
30 Sep 2029,4603,73711,6282,629
30 Jun 2028,4413,52011,6472,396
31 Mar 2027,7363,18711,9892,140
31 Dec 1928,5853,32212,5242,041
30 Sep 1928,0042,67712,3761,655
30 Jun 1927,2322,66412,0481,620
31 Mar 1925,9292,71411,3101,596
31 Dec 1824,9182,70810,7341,480
30 Sep 1823,7162,79910,1361,441
30 Jun 1822,0402,9969,3151,274
31 Mar 1820,3723,0928,1951,304
31 Dec 1718,5343,1247,5371,027
30 Sep 1716,9513,0476,856700
30 Jun 1716,0452,9936,421461
31 Mar 1715,2832,9086,4040
31 Dec 1614,6292,8056,0280
30 Sep 1614,1732,7455,5160
30 Jun 1613,6242,6575,2130
31 Mar 1613,0342,5574,8980
31 Dec 1512,6092,4594,7240
30 Sep 1512,4382,4294,5750
30 Jun 1512,4082,3984,3810
31 Mar 1512,1682,2344,1590
31 Dec 1412,0262,1134,0070
30 Sep 1411,5872,2073,7600
30 Jun 1411,0261,9873,5700
31 Mar 1410,5981,6463,4650
31 Dec 139,9961,5833,2730

Quality Earnings: 2196 has a large one-off loss of CN¥1.1B impacting its last 12 months of financial results to 30th September, 2024.

Growing Profit Margin: 2196's current net profit margins (5.1%) are lower than last year (8.3%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 2196's earnings have declined by 5.9% per year over the past 5 years.

Accelerating Growth: 2196's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 2196 had negative earnings growth (-40.9%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (9.4%).

Return on Equity

High ROE: 2196's Return on Equity (4.7%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 14:27
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is covered by 31 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ling ZhangBNP Paribas Securities (Asia)
Wai Chak YuenBOCI Research Ltd.
Yang HuangBofA Global Research